OPIOIDS IN PAIN SYNDROME MANAGEMENT (part 1)
https://doi.org/10.21292/2078-5658-2017-14-3-58-67
Abstract
The goal of this review is to inform doctors about new opioids currently used for routine medical practice in the most developed countries. This publication contains brief history, describes main mechanisms of opioid action, types and specific functioning of opioid receptors, it presents pharmacological parameters of the most frequently used opioids and their specific use in the clinical practice. In the light of increased interest towards pain management with opioids, the article will be useful for broad audience of doctors treating acute and chronic pain.
About the Authors
D. M. Arbuck
http://www.IndianaPolyclinic.com
Indiana Polyclinic, Indianapolis
United States
President of Indiana Polyclinic, Indianapolis, USA Clinical Professor, Associate of Pain and Psychiatry
Indiana Polyclinic, Indianapolis
United States
President of Indiana Polyclinic, Indianapolis, USA Clinical Professor, Associate of Pain and Psychiatry
G. R. Abuzarova
Center of Palliative Care for Cancer Patients, Moscow
Russian Federation
Doctor of Medical Sciences, Head of the Center of Palliative Care for Cancer Patients
Russian Federation
Doctor of Medical Sciences, Head of the Center of Palliative Care for Cancer Patients
G. S. Alekseeva
National Medical Research Radiological Center, Moscow
Russian Federation
Doctor of Medical Sciences, Deputy General Director for Therapy
Russian Federation
Doctor of Medical Sciences, Deputy General Director for Therapy
References
1. Arbuck D. Management of Opioid Tolerability and Adverse Effects. J. Med., 2010, vol. 3, no. 1, pp. 1-10.
2. Coda B.A., Rudy A.C. Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers. Anesth. Analg., 2003, vol. 97, no. 1, pp. 117-123.
3. Curhan S.G., Eavey R., Shargorodsky J. et al. Analgesic use and the risk of hearing loss in men. Am. J. Med., 2010, vol. 123, no. 3, pp. 231-237.
4. Davis M.P. Opioids for cancer pain. (2 edition.). Oxford UK: Oxford University Press. 2009, 487 p.
5. Davis M.P. Fentanyl for breakthrough pain: a systematic review. Expert Review Neurother., 2011, vol. 11, no. 8, pp. 1197-1216.
6. Davis M.P., Walsh D. Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer, 2001, vol. 9, pp. 73-83.
7. Foley K. The treatment of cancer pain. NEJM, 1985, vol. 313, pp. 84-95.
8. Friesen C., Roscher M. Methadone, commonly used as maintenance medication for outpatient treatment of opioid dependence, kills leukemia cells and overcomes chemoresistance. Cancer Research, 2008, vol. 68, no. 15, pp. 6059-6064.
9. Gardiner S.J., Begg E.J. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacological Reviews, 2006, vol. 58, no. 3, pp. 521-590.
10. Gasche Y., Daali Y., Fathi M. et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. December, 2004, vol. 351, no. 27, pp. 2827-2831.
11. Gregory L.H. Opioid metabolism and effects of cytochrome P450. Pain Medicine, 2009, vol. 10, issue supplement s1, pp. S1-S48.
12. Ho T., Vrabec J.T., Burton A.W. Hydrocodone use and sensorineural hearing loss. Pain Physician, 2007, vol. 10, no. 3, pp. 467-672.
13. http://www.sciencedaily.com/releases/2010/03/100314150916.htm
14. Information for Healthcare Professionals: Fentanyl Transdermal System (marketed as Duragesic and generics) − 12/21/2007 Update. Postmarket Drug Safety Information for Patients and Providers. FDA. December 21 2007.
15. Instructions for Mean Equivalent Daily Dose (MEDD). Retrieved 2015−09−30 https://files.medical.ca.gov/pubsdoco/dur/articles/dured_24035.pdf
16. International Narcotics Control Board (2009). Narcotic drugs: estimated world requirements for 2009; statistics for 2007. Report E/INCB/2008/2 New York: United Nations
17. Janecka A., Fichna J., Janecki T. Opioid receptors and their ligands. Curr. Top. Med. Chem., 2004, vol. 1, pp. 1-17.
18. John J., Amley X. Torsade de pointes due to methadone use in a patient with HIV and hepatitis C coinfection. Cardiology Research and Practice, 2010, pp. 1-4.
19. Kilpatrick G.J., Smith T.W. Morphine-6-glucuronide: actions and mechanisms. Med. Res. Rev., 2005, vol. 25, no. 5, pp. 521-544.
20. Landau R., Stamer U.M., Landau R. Pharmacogenomic considerations in opioid analgesia. Pharmacogenomics and Personalized Medicine, 2012, vol. 5, pp. 73-87.
21. Mangione M.P., Matoka M. Improving Pain Management Communication. How patients understand the terms «Opioid» and «Narcotic». J. General Internal Med., 2008, vol 23, no. 9, pp. 1336-1338.
22. Maremmani I., Pacini M. QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur. Addiction Research, 2005, vol. 11, no. 1, pp. 44-49.
23. Mayes S., Ferrone M. Fentanyl HCl patient-controlled iontophoretic transdermal system for pain: pharmacology. Ann. Pharmacother., 2006, vol. 40, no. 12, pp. 2178-2186.
24. Medical University of South Carolina Pharmacy and Therapeutic Committee Guidelines http://mcintranet.musc.edu/agingq3/calculationswesbite/convchart. pdf
25. Mercadante S., Portenoy R.K. Breakthrough cancer pain: twenty-five years of study. December 2016, vol. 157, no. 12, www.painjournalonline.com
26. Meyer M.R., Maurer H.H. Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics, 2011, vol. 12, no. 2, pp. 215-223.
27. Michael J.B. The clinical implications of Cytochrome P450 interactions with opioids and strategies for pain management. J. Pain Sympt. Management, 2012, vol. 44, no. 6S, pp. 15-22.
28. Michael S. Guide to Pain Management in Low-Resource Settings, Chapter 7. Opioids in Pain Medicine: 39-47.
29. Modified from Pain Physician 2011; 14: E343−360 This is a document from the site www.dolor.org.co
30. Nock B., Giordano A.L. Properties of the putative epsilon opioid receptor: identification in rat, guinea pig, cow, pig and chicken brain. JPET January, 1993, vol. 264, no. 1, pp. 349-359.
31. Odell L.R., Skopec J., McCluskey A. Isolation and identification of unique marker compounds from the Tasmanian poppy Papaver somniferum N. Implications for the identification of illicit heroin of Tasmanian origin. Forensic Sci. Int. March, 2008, vol. 175, no. 2–3, pp. 202-208.
32. Ohio Department of Rehabilitation and correction News release November 13, 2009.
33. Pereira J., Lawlor P. equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing. J. Pain Symptom Manage., 2001, vol. 22, pp. 672-687.
34. Pert C.B., Snyder S.H. Opiate receptor: demonstration in nervous tissue. Science, 1973, vol. 179, pp. 1011-1014.
35. Rowell F., Seymour R., Rawlins M. Pharmacokinetics of intravenous and oral dihydrocodeine and its acid metabolites. Eur. J. Clin. Pharmacol., 1983, vol. 25, no. 3, pp. 419-424.
36. Savoia G., Loreto M., Gravino E. Sufentanil: an overview of its use for acute pain management . Minerva Anestesiologica, 2001, vol. 67, 9 suppl. 1, pp. 206-216.
37. Smith W. A dictionary of greek and roman biography and mythology. 2007, London, United Kingdom, I.B. Tauris, 1 ed.
38. Stanley T.H. The history and development of the fentanyl series. J. Pain Symptom Manage., 1992, vol. 7, 3 suppl., pp. S3–S7.
39. Stein C., Schäfer M., Machelska H. Attacking pain at its source: new perspectives on opioids. Nature Med., 2003, vol. 9, no. 8, pp. 1003-1008.
40. The American Society of Health-System Pharmacists. Codeine. Retrieved 3 April 2011.
41. Trescot A., Datta S. еt al. Opioid pharmacology. Pain Physician, 2008, Opioid Special Issue, 11, pp. S133−S153.
42. Webster L.R., Cochella S. An analysis of the root causes for opioid related overdose deaths in the US. Pain Med., 2011, vol. 12, suppl. 2. pp. 26-35.
Review
For citations:
Arbuck D.M., Abuzarova G.R., Alekseeva G.S. OPIOIDS IN PAIN SYNDROME MANAGEMENT (part 1). Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2017;14(3):58-67. (In Russ.) https://doi.org/10.21292/2078-5658-2017-14-3-58-67
Email this article 